Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

145.39USD
8:59pm GMT
Change (% chg)

$0.61 (+0.42%)
Prev Close
$144.78
Open
$144.78
Day's High
$147.63
Day's Low
$144.70
Volume
86,856
Avg. Vol
150,111
52-wk High
$163.69
52-wk Low
$128.58

Select another date:

Thu, Dec 21 2017

BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)

* JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA

Pennsylvania man admits to trading on tips about drug company

A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired.

Pennsylvania man admits to trading on tips about drug company

Dec 15 A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired.

BRIEF-Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

* JAZZ PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DANIEL SWISHER AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Jazz Pharmaceuticals posts Q3 EPS of $1.03

* Jazz pharmaceuticals announces third quarter 2017 financial results

BRIEF-Jazz Pharma submits Vyxeo Marketing Authorization Application to European Medicines Agency

* Jazz Pharmaceuticals submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for treatment of certain types of high-risk acute myeloid leukemia Source text for Eikon: Further company coverage:

Select another date: